Cara Therapeutics | CARA - Current Assets


Cara Therapeutics reported $23.13M in Current Assets for its fiscal quarter ending in September of 2026.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.27B 43.88M Sep/2026
Alterity Therapeutics Limited AUD 37.91M 15.92M Dec/2025
Cara Therapeutics USD 23.13M 2.2M Sep/2026
Cassava Sciences USD 80.06M 3.67M Sep/2026
Chugai Pharma JPY 1.64T 65.29B Sep/2026
Cipla INR 250.61B 9.14B Sep/2026
Clal Biotechnology ILS 14.69M 1.95M Dec/2023
Compugen USD 129.41M 7.88M Jun/2026
CSL USD 11.85B 1000K Dec/2025
Grifols EUR 5.96B 316.31M Dec/2025
Halozyme Therapeutics USD 1.85B 913.71M Sep/2026
J&J USD 56.35B 3.42B Sep/2026
Neurocrine Biosciences USD 2.01B 370.7M Sep/2026
Pacira USD 10.3B 9.68B Sep/2026
Pfizer USD 45.01B 3.65B Sep/2026
RedHill Biopharma USD 8.57M 2.05M Jun/2026
Supernus Pharmaceuticals USD 711.21M 12.28M Sep/2026
Vanda Pharmaceuticals USD 347.26M 20.23M Dec/2025